Neuropathic Pain Market, By Drug Class (Tricyclic Anti-Depressant, Anticonvulsant, Local Anaesthesia, Opioids, Steroids, Others), By Indication (Diabetic neuropathy, Chemotherapy-induced Peripheral neuropathy, Other), By Distribution Channel (Retail Pharm

Neuropathic Pain Market, By Drug Class (Tricyclic Anti-Depressant, Anticonvulsant, Local Anaesthesia, Opioids, Steroids, Others), By Indication (Diabetic neuropathy, Chemotherapy-induced Peripheral neuropathy, Other), By Distribution Channel (Retail Pharmacies, Drug Store, Online Pharmacies), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Neuropathic pain is a condition which involves pain caused due to damage or diseases affecting the nervous system. These conditions may include diseases such as diabetes causing diabetic neuropathy, chemotherapy induced neuropathic pain, and trigeminal neuralgia. Diabetic neuropathy is the damage caused to the nerve due to diabetes which often leads to pain and numbness in feet or lower legs. The pain can be experienced in other parts of the body such as hips, wrist and back depending upon the effect of neuropathy. There are different types of neuropathy such as focal neuropathy, proximal neuropathy, peripheral neuropathy and autonomic neuropathy. An estimated 50% of diabetic population suffers from diabetic neuropathy across the globe. Further, as per CDC estimates, 6-7 people per 1000 diabetic population suffer from diabetic neuropathy in the U.S.

Restraints of the Global Neuropathic Pain Market

Factors such as availability of less number of FDA approved medications, and incomplete pain relief, are expected to restrain growth of the global neuropathic pain market.

Key features of the study:

This report provides in-depth analysis of the global neuropathic pain market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
It profiles leading players in the global neuropathic pain market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Pfizer, Inc., Johnson & Johnson Services, Inc., Sanofi S.A., Eliy Lily and Company, GlaxoSmithKline PLC, Biogen Idec., Bristol-Myers Sqibb, Baxter Healthcare Corporation, and Depomed, Inc.
Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
The global neuropathic pain market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

Global Neuropathic Pain Market, By Drug Class:
Tricyclic Anti-Depressant
Anticonvulsant
Local Anaesthesia
Opioids
Steroids
Others
Global Neuropathic Pain Market, By Indication:
Diabetic neuropathy
Chemotherapy-induced Peripheral neuropathy
Other
Global Neuropathic Pain Market, By Distribution Channel:
Retail Pharmacies
Drug Store
Online Pharmacies
Global Neuropathic Pain Market, By Geography:
North America
By Drug Class
Tricyclic Anti-Depressant
Anticonvulsant
Local Anaesthesia
Opioids
Steroids
Others
By Indication
Diabetic neuropathy
Chemotherapy-induced Peripheral neuropathy
Other
By Distribution Channel
Retail Pharmacies
Drug Store
Online Pharmacies
By Country:
U.S.
Canada
Europe
By Drug Class
Tricyclic Anti-Depressant
Anticonvulsant
Local Anaesthesia
Opioids
Steroids
Others
By Indication
Diabetic neuropathy
Chemotherapy-induced Peripheral neuropathy
Other
By Distribution Channel
Retail Pharmacies
Drug Store
Online Pharmacies
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Class
Tricyclic Anti-Depressant
Anticonvulsant
Local Anaesthesia
Opioids
Steroids
Others
By Indication
Diabetic neuropathy
Chemotherapy-induced Peripheral neuropathy
Other
By Distribution Channel
Retail Pharmacies
Drug Store
Online Pharmacies
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
By Drug Class
Tricyclic Anti-Depressant
Anticonvulsant
Local Anaesthesia
Opioids
Steroids
Others
By Indication
Diabetic neuropathy
Chemotherapy-induced Peripheral neuropathy
Other
By Distribution Channel
Retail Pharmacies
Drug Store
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Middle East:
By Drug Class
Tricyclic Anti-Depressant
Anticonvulsant
Local Anaesthesia
Opioids
Steroids
Others
By Indication
Diabetic neuropathy
Chemotherapy-induced Peripheral neuropathy
Other
By Distribution Channel
Retail Pharmacies
Drug Store
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug Class
Tricyclic Anti-Depressant
Anticonvulsant
Local Anaesthesia
Opioids
Steroids
Others
By Indication
Diabetic neuropathy
Chemotherapy-induced Peripheral neuropathy
Other
By Distribution Channel
Retail Pharmacies
Drug Store
Online Pharmacies
By Country/Region:
Central Africa
South Africa
North Africa
Company Profiles
Pfizer, Inc.*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Johnson & Johnson Services, Inc.
Sanofi S.A.
Eily Lily and Company
GlaxoSmithKline PLC
Biogen Idec.
Bristol-Myers Squibb
Baxter Healthcare Corporation
Depomed, Inc.

“*” marked represents similar segmentation in other categories in the respective section.